Signpath Pharma
Phase 2Signpath has developed a platform technology (the CorreQT platform) which mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy.
Founded
2007
Focus
Drug Delivery
About
Signpath has developed a platform technology (the CorreQT platform) which mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy.
Company Info
TypePrivate
Founded2007
LocationPhiladelphia, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile